Skip to content

Fabry Exercise Intolerance Study

Fabry Exercise Intolerance Study (FEISTY)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05413876
Acronym
FEISTY
Enrollment
30
Registered
2022-06-10
Start date
2021-10-10
Completion date
2024-01-02
Last updated
2023-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fabry Disease, Fabry Disease, Cardiac Variant

Brief summary

Patients and healthy controls will undergo cardiopulmonary exercises and testing of the muscles strength to gain additional understanding of exercise intolerance as Fabry disease (FD) manifestation. An additional needle muscle biopsy may be performed. Tissue analysis from this biopsy will include evaluation of the lipidomics profile and mitochondrial function. Results of the tests and any potential exercise intolerance will be compared against healthy, age-, sex- and BMI-matched volunteers. The hypothesis is that patients with FD will have reduced exercise capacity due to changes in skeletal and cardiac muscle energy metabolism.

Detailed description

Background: Fabry disease (FD) is an inherited, highly variable and slowly progressive X linked disorder, which predominantly affects vascular endothelium, the heart, kidneys and the brain. Exercise intolerance is a complaint expressed by the majority of patients, at all stages of the disease. The exact cause, extent and development over time of exercise intolerance in FD in insufficiently understood. This limits preventive measures and adequate treatment. Hypothesis: 1) The development of energy metabolism in skeletal and cardiac muscle in FD is disturbed early on in disease development and this progresses as the disease worsens, resulting in reduced exercise capacity. 2) Intermittent CPX is an objective and sensitive tool to grade the level of exercise tolerance in FD patients and yields specific outcome parameters that can be used in future intervention studies. Primary objectives: 1) To study the presence and extent of exercise intolerance in male, female FD patients with classical FD and men with non-classical FD, in different stages of the disease. 2) To determine the aetiology of exercise intolerance in FD. Secondary objectives: 1) To determine whether the exercise test protocol used in this study can be used as a clinical outcome measure in future intervention studies. 2) To investigate difference in the time-relation between V'O2 and circulatory, ventilatory and metabolic variables during intermittent exercise between FD patients groups (potentially providing an indication of the source of possibly slowed V'O2 kinetics). Methods: This study will consist of two screening visits, one testing procedure visit, and an optional second visit for all subjects enrolled in the study. During the first testing visit two cardiopulmonary exercise (CPX) test will be performed. During the CPX tests gas exchange, ventilation, blood pressure and cardiac output will be measured and exhaustion level monitored. Before and after the tests a blood sample will be taken. The upper leg muscle strength and the leg muscle size will be assessed. In order to detect alterations in skeletal muscle energy metabolism, a needle biopsy of the upper leg muscle will be taken during the second optional study visit. In the biopsy specimen, lipidomics profile, electronic microscopic characteristics of muscle tissue and mitochondrial function will be assessed.

Interventions

Exercise test with step-change from rest to a relatively low constant workload.

Exercise test with incremental workload until maximal workload.

Sponsors

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* FD patients: Men and women with a definite known diagnosis of FD. * Healthy controls: Healthy control subjects (men and women) with an age of 18 years of older.

Exclusion criteria

FD patients: * Pregnancy * Recent acute myocardial infarct (\<6 months) * Uncontrolled arrhythmia/severe conduction disorder (atrial fibrillation or second/third-degree AV block) causing hemodynamic compromise * Implantable pacemaker or other cardiac device with complete ventricular pacing * Uncontrolled heart failure with hemodynamic compromise * Uncontrolled hypertension (Systolic Blood Pressure \>150 mmHg and Diastolic Blood Pressure \>100 mmHg on repeated measurements) * Active infection, anaemia, severe renal dysfunction (estimated Glomerular filtration rate \<30 ml/min/1,73m2) likely to significantly impact on exercise performance * In some cases: use of anticoagulants or anti platelet therapy (see study procedure) Healthy controls: * All abovementioned

Design outcomes

Primary

MeasureTime frameDescription
Mitochondrial function of muscle tissueBiopsy at baselineSkeletal muscle alterations
Ventilation reserve (L)During maximum exercise (max 30 min).Pulmonary involvement/Skeletal muscle alterations
CO2 ventilation equivalent (L/L)During maximum exercise (max 30 min).Pulmonary involvement/Cardiac dysfunction
O2 saturation (%)During maximum exercise (max 30 min).Pulmonary involvement/Cardiac dysfunction
Cardiac Output (L/min)During maximum exercise (max 30 min).Cardiac dysfunction
Heart rate reserve (per minute)During maximum exercise (max 30 min).Cardiac dysfunction:
Muscle size on echography (cm)BaselineSkeletal muscle alterations
Muscle strength via resistance test (kg)Biopsy at baselineSkeletal muscle alterations
Lipidomics profile of muscle tissueBiopsy at baselineSkeletal muscle alterations
Electronic microscopic characteristics of muscle tissueBiopsy at baselineSkeletal muscle alterations
Differences in V'O2 max kinetics (ml/kg/min)At rest (baseline) and after maximum CPX test (30 min)
Tiffeneau-index (FEV1/IVC ratio)At rest (baseline)Pulmonary involvement
Anaerobic threshold (ml/kg/min)During maximum exercise (max 30 min).Pulmonary involvement/Cardiac dysfunction/Skeletal muscle alterations

Secondary

MeasureTime frame
Correlation between V'O2 kinetics during intermittent exercise and V'O2 max on the incremental maximum CPX (Pearson correlation coefficient).Day 1
Correlation between V'O2 kinetics during intermittent exercise and activity score on the SQUASH Questionnaire (Pearson correlation coefficient).Day 1
Correlation between V'O2 kinetics during intermittent exercise and functional and morphological cardiac parameters on cardiac imaging (Magnetic resonance or echocardiography) (Pearson correlation coefficient).Day 1

Other

MeasureTime frame
Lactate (mmol/L)Baseline and after maximum exercise
Haemoglobin (mmol/L)Baseline
Body weight (kg)Baseline
Body height (cm)Baseline
NT-proBNP (ng/L)Baseline
Troponin (μg/L)Baseline

Countries

Netherlands

Contacts

Primary ContactBram Veldman, MD
b.c.f.veldman@amsterdamumc.nl0031205666791

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026